Diabetic Nephropathy Treatment Market by Treatment Type (End-stage Renal Disease (ESRD) Treatment, Medications, Pharmacological Treatment), End-User (Hospitals, Nephrology Clinics) - Global Forecast 2024-2030

Diabetic Nephropathy Treatment Market by Treatment Type (End-stage Renal Disease (ESRD) Treatment, Medications, Pharmacological Treatment), End-User (Hospitals, Nephrology Clinics) - Global Forecast 2024-2030


The Diabetic Nephropathy Treatment Market size was estimated at USD 2.26 billion in 2023 and expected to reach USD 2.38 billion in 2024, at a CAGR 5.46% to reach USD 3.28 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Diabetic Nephropathy Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Diabetic Nephropathy Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Nephropathy Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, ChemoCentryx, Inc., Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo International PLC, IQVIA Inc., Johnson & Johnson Services, Inc., Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Mesoblast Ltd, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Reata Pharmaceuticals, Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Diabetic Nephropathy Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment Type
End-stage Renal Disease (ESRD) Treatment
Kidney Dialysis
Transplant

Medications
Angiotensin 2 Receptor Blockers (ARBs)
Angiotensin-converting Enzyme (ACE) Inhibitors
Cholesterol-lowering Drugs
Metformin

Pharmacological Treatment
End-User
Hospitals

Nephrology Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Diabetic Nephropathy Treatment Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Diabetic Nephropathy Treatment Market?
3. What are the technology trends and regulatory frameworks in the Diabetic Nephropathy Treatment Market?
4. What is the market share of the leading vendors in the Diabetic Nephropathy Treatment Market?
5. Which modes and strategic moves are suitable for entering the Diabetic Nephropathy Treatment Market?PDF E-mail From Publisher (2-5)Users License


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Diabetic Nephropathy Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising global prevalence of diabetes with increasing geriatric population
5.1.1.2. Government-led initiatives to address the burden of diabetes and its complications
5.1.1.3. Growing emphasis on patient-centric care plans for diabetic nephropathy
5.1.2. Restraints
5.1.2.1. High cost of diabetic nephropathy treatments
5.1.3. Opportunities
5.1.3.1. Introduction of new and more effective diabetic nephropathy treatments
5.1.3.2. Improved reimbursement policies and healthcare coverage for diabetic nephropathy treatments
5.1.4. Challenges
5.1.4.1. Comorbidities and complexity of care associated with diabetic nephropathy
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Diabetic Nephropathy Treatment Market, by Treatment Type
6.1. Introduction
6.2. End-stage Renal Disease (ESRD) Treatment
6.3.1. Kidney Dialysis
6.3.2. Transplant
6.3. Medications
6.4.1. Angiotensin 2 Receptor Blockers (ARBs)
6.4.2. Angiotensin-converting Enzyme (ACE) Inhibitors
6.4.3. Cholesterol-lowering Drugs
6.4.4. Metformin
6.4. Pharmacological Treatment
7. Diabetic Nephropathy Treatment Market, by End-User
7.1. Introduction
7.2. Hospitals
7.3. Nephrology Clinics
8. Americas Diabetic Nephropathy Treatment Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Diabetic Nephropathy Treatment Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Diabetic Nephropathy Treatment Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Abbott Laboratories
12.1.2. AbbVie Inc.
12.1.3. Amgen Inc.
12.1.4. AstraZeneca PLC
12.1.5. Aurobindo Pharma Limited
12.1.6. Bayer AG
12.1.7. Boehringer Ingelheim International GmbH
12.1.8. Bristol-Myers Squibb Company
12.1.9. ChemoCentryx, Inc.
12.1.10. Daiichi Sankyo Company, Limited
12.1.11. Dr. Reddy's Laboratories Ltd.
12.1.12. Eli Lilly and Company
12.1.13. Endo International PLC
12.1.14. IQVIA Inc.
12.1.15. Johnson & Johnson Services, Inc.
12.1.16. Mallinckrodt Pharmaceuticals
12.1.17. Merck & Co., Inc.
12.1.18. Mesoblast Ltd
12.1.19. Novartis AG
12.1.20. Otsuka Pharmaceutical Co., Ltd.
12.1.21. Pfizer, Inc.
12.1.22. Reata Pharmaceuticals, Inc.
12.1.23. Sanofi SA
12.1.24. Sun Pharmaceutical Industries Ltd.
12.1.25. Teva Pharmaceutical Industries Ltd.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. DIABETIC NEPHROPATHY TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. DIABETIC NEPHROPATHY TREATMENT MARKET DYNAMICS
FIGURE 7. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 8. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 10. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. DIABETIC NEPHROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. DIABETIC NEPHROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings